Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to stall ALK-Positive lung cancer

NCT ID NCT05200481

Ongoing Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether adding chemotherapy to the targeted drug brigatinib helps people with advanced ALK-positive non-small cell lung cancer live longer without their cancer growing. About 110 people who have not had treatment for advanced disease will receive either brigatinib alone or brigatinib plus two chemotherapy drugs (carboplatin and pemetrexed). The main goal is to see how many are still cancer-free after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Brigatinib (a targeted drug) and carboplatin-pemetrexed (chemotherapy)
What this could lead to
If successful, this could show that adding chemotherapy to brigatinib improves how long the cancer stays under control for people with ALK-positive lung cancer.
What could go wrong
This is a phase 2 trial with only 110 people, so results are preliminary. The combination may cause more side effects, and it's not yet known if it works better than brigatinib alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK GENE MUTATION NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • CHU Besançon - Hôpital J. MINJOZ

    Besançon, 25030, France

  • CHU Côte de Nacre

    Caen, 14000, France

  • CHU Dupuytren

    Limoges, 87042, France

  • CHU Rennes - Hôpital Pontchaillou

    Rennes, 35033, France

  • CHU d'Angers

    Angers, 49033, France

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54511, France

  • Centre Georges-François Leclerc

    Dijon, 21079, France

  • Centre Hospitalier

    Mulhouse, 68070, France

  • Centre Hospitalier

    Saint-Quentin, 02100, France

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, 94000, France

  • Centre Hospitalier de Villefranche-sur-Saône

    Villefranche-sur-Saône, 69655, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Chu Grenoble

    Grenoble, 38043, France

  • HIA Sainte-Anne

    Toulon, 83800, France

  • Hospices Civils de Lyon - Hôpital Louis Pradel

    Bron, 69677, France

  • Hôpital APHP Ambroise Paré

    Boulogne, 92104, France

  • Hôpital Arnaud de Villeneuve

    Montpellier, 34295, France

  • Hôpital BICHAT

    Paris, 75877, France

  • Hôpital Calmette

    Lille, 59037, France

  • Hôpital Charles Nicolle

    Rouen, 76031, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Haut-Lévèque

    Pessac, 33604, France

  • Hôpital Larrey (CHU)

    Toulouse, 31059, France

  • Hôpital Nord

    Marseille, 13915, France

  • Hôpital TENON

    Paris, 75970, France

  • Institut Paoli Calmettes

    Marseille, 13273, France

  • Institut de Cancérologie de l'Ouest - René Gauducheau

    Saint-Herblain, 44805, France

  • Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.